These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31972148)

  • 1. Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis.
    Paquette M; Gauthier D; Chamberland A; Prat A; De Lucia Rolfe E; Rasmussen JJ; Kaduka L; Seidah NG; Bernard S; Christensen DL; Baass A
    Clin Biochem; 2020 Mar; 77():20-25. PubMed ID: 31972148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis.
    Emma MR; Giannitrapani L; Cabibi D; Porcasi R; Pantuso G; Augello G; Giglio RV; Re NL; Capitano AR; Montalto G; Soresi M; Cervello M
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Dec; 1865(12):158792. PubMed ID: 32777481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population.
    Wargny M; Ducluzeau PH; Petit JM; Le May C; Smati S; Arnaud L; Pichelin M; Bouillet B; Lannes A; Blanchet O; Lefebvre P; Francque S; Van Gaal L; Staels B; Vergès B; Boursier J; Cariou B
    Atherosclerosis; 2018 Nov; 278():82-90. PubMed ID: 30261472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver fat accumulation is associated with circulating PCSK9.
    Ruscica M; Ferri N; Macchi C; Meroni M; Lanti C; Ricci C; Maggioni M; Fracanzani AL; Badiali S; Fargion S; Magni P; Valenti L; Dongiovanni P
    Ann Med; 2016 Aug; 48(5):384-91. PubMed ID: 27222915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Plasma Proprotein Convertase Subtilisin/Kexin Type 9 and the Presence of Metabolic Syndrome in a Predominantly Rural-Based Sub-Saharan African Population.
    Paquette M; Luna Saavedra YG; Chamberland A; Prat A; Christensen DL; Lajeunesse-Trempe F; Kaduka L; Seidah NG; Dufour R; Baass A
    Metab Syndr Relat Disord; 2017 Oct; 15(8):423-429. PubMed ID: 28749722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing
    Lebeau PF; Byun JH; Platko K; MacDonald ME; Poon SV; Faiyaz M; Seidah NG; Austin RC
    J Biol Chem; 2019 Jun; 294(23):9037-9047. PubMed ID: 31004037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of circulating proprotein convertase subtilisin/kexin type 9 levels and the risk of incident type 2 diabetes in subjects with prediabetes: a population-based cohort study.
    Shi J; Zhang W; Niu Y; Lin N; Li X; Zhang H; Hu R; Ning G; Fan J; Qin L; Su Q; Yang Z
    Cardiovasc Diabetol; 2020 Dec; 19(1):209. PubMed ID: 33302966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.
    Rosoff DB; Bell AS; Wagner J; Mavromatis LA; Hamandi A; Park L; Jung J; Lohoff FW
    Cell Mol Gastroenterol Hepatol; 2024; 17(1):29-40. PubMed ID: 37703945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variations in TM6SF2, PCSK9 and PCSK7 genes and risk of hepatic steatosis after liver transplantation: a cross-sectional study.
    Eshraghian A; Moasser E; Azarpira N; Fattahi MR; Nikeghbalian S; Malek-Hosseini SA; Geramizadeh B
    BMC Gastroenterol; 2021 Dec; 21(1):458. PubMed ID: 34876018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells.
    Chao TH; Chen IC; Li YH; Lee PT; Tseng SY
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.
    Ruscica M; Ferri N; Fogacci F; Rosticci M; Botta M; Marchiano S; Magni P; D'Addato S; Giovannini M; Borghi C; Cicero AFG;
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28468788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study.
    Peng J; Liu MM; Jin JL; Cao YX; Guo YL; Wu NQ; Zhu CG; Dong Q; Sun J; Xu RX; Li JJ
    Cardiovasc Diabetol; 2020 Oct; 19(1):167. PubMed ID: 33023603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics.
    Gauthier MS; Awan Z; Bouchard A; Champagne J; Tessier S; Faubert D; Chabot K; Garneau PY; Rabasa-Lhoret R; Seidah NG; Ridker PM; Genest J; Coulombe B
    J Clin Lipidol; 2018; 12(4):1027-1038. PubMed ID: 29699916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating proprotein convertase subtilisin-kexin type 9, all-cause mortality, and cardiovascular mortality: The Ludwigshafen Risk and Cardiovascular Health study.
    Silbernagel G; Scharnagl H; Kleber ME; Stojakovic T; März W
    Eur J Prev Cardiol; 2017 Jul; 24(10):1095-1101. PubMed ID: 28436724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased serum PCSK9, a potential biomarker to screen for periodontitis, and decreased total bilirubin associated with probing depth in a Japanese community survey.
    Tabeta K; Hosojima M; Nakajima M; Miyauchi S; Miyazawa H; Takahashi N; Matsuda Y; Sugita N; Komatsu Y; Sato K; Ishikawa T; Akiishi K; Yamazaki K; Kato K; Saito A; Yoshie H
    J Periodontal Res; 2018 Jun; 53(3):446-456. PubMed ID: 29516504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between proprotein convertase subtilisin/kexin type 9 and late saphenous vein graft disease after coronary artery bypass grafting: a cross-sectional study.
    Gao J; Wang HB; Xiao JY; Ren M; Reilly KH; Li YM; Liu Y
    BMJ Open; 2018 Jul; 8(7):e021951. PubMed ID: 29991632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of PCSK9 in metabolic dysfunction-associated steatotic liver disease and its impact on bariatric surgery outcomes.
    Castellano-Castillo D; Núñez-Sánchez MÁ; Balaguer-Román A; Martínez-Sánchez MA; Fernández-Ruiz VE; Ferrer-Gómez M; Martínez CM; Frutos MD; Queipo-Ortuño MI; Cardona F; Ramos-Molina B
    Surg Obes Relat Dis; 2024 Jul; 20(7):652-659. PubMed ID: 38490825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience.
    Scicali R; Di Pino A; Urbano F; Ferrara V; Marchisello S; Di Mauro S; Scamporrino A; Filippello A; Rabuazzo AM; Purrello F; Piro S
    Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):869-879. PubMed ID: 33549441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between circulating proprotein convertase subtilisin/kexin type 9 levels and prognosis in patients with severe chronic kidney disease.
    Rasmussen LD; Bøttcher M; Ivarsen P; Jørgensen HS; Nyegaard M; Buttenschøn H; Gustafsen C; Glerup S; Bøtker HE; Svensson M; Winther S
    Nephrol Dial Transplant; 2020 Apr; 35(4):632-639. PubMed ID: 30137516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.